EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Anticoagulant drugs targeting factor XI/XIa and coagulation tests: we urgently need reliable pharmacodynamic data

Isabelle Gouin-Thibault, Thomas Lecompte, Dominique Lasne

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.02.025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Isabelle Gouin-Thibault und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Hematology, University Hospital of Rennes, Institut de Recherche en Santé, environnement et travail-INSERM-1085, University …. Hauptthemen laut MEDLINE: Anticoagulants, Blood Coagulation, Factor XI, Factor XIa. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antifactor (F)XI/FXIa anticoagulants under development include antisense oligonucleotides, monoclonal antibodies, and small molecules. They do not require routine monitoring, but knowledge of their impact on coagulation tests is essential in view of their expected widespread use. A concentration-dependent prolongation of activated partial thromboplastin time has been shown but varies according to reagents, and the lack of comprehensive data makes interpretation of this test difficult. Measurement of FXI clotting activity is relevant only in case of treatment with antisense oligonucleotides. Measurement of contact pathway factors, if required, should be performed after multiple dilutions of the plasma sample to overcome any inhibitory effect of the anticoagulant. All other tests used in clinical trials (FXIa, FXI antigenic method, and specific thrombin generation assay) are not implemented in clinical laboratories. More comprehensive information on the effect of anti-FXI/FXIa anticoagulants on coagulation tests is urgently needed to anticipate the use of these drugs once they are approved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsBlood CoagulationFactor XIFactor XIaHumansBlood Coagulation TestsPartial Thromboplastin TimePredictive Value of TestsOligonucleotides, AntisenseDrug MonitoringReproducibility of ResultsAnimals

Stichwörter der Autor:innen

APTTanticoagulantsfactor XI inhibitorsfactor XIa inhibitors

Substanzen

AnticoagulantsFactor XIFactor XIaOligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Laboratory Hematology, University Hospital of Rennes, Institut de Recherche en Santé, environnement et travail-INSERM-1085, University of Rennes, Rennes, France. Electronic address: isabelle.gouin@chu-renn…
  • Vascular Medicine Division, University Hospital of Nancy, University of Lorraine, Nancy, France.
  • Department of Laboratory Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, INSERM UMRS_1176, Paris, France.

Zitieren

APA

Gouin-Thibault, I., Lecompte, T., & Lasne, D. (2025). Anticoagulant drugs targeting factor XI/XIa and coagulation tests: we urgently need reliable pharmacodynamic data. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.02.025

Vancouver

Gouin-Thibault I, Lecompte T, Lasne D. Anticoagulant drugs targeting factor XI/XIa and coagulation tests: we urgently need reliable pharmacodynamic data. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.02.025

BibTeX
@article{GouinThibault2025,
  author = {Gouin-Thibault, Isabelle and Lecompte, Thomas and Lasne, Dominique},
  title = {Anticoagulant drugs targeting factor XI/XIa and coagulation tests: we urgently need reliable pharmacodynamic data},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.02.025}
}
Kostenlos starten →